J. Cohen

发表

Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase.

S. Ng, D. Augeri, P. Kovar, 1999, Bioorganic & medicinal chemistry letters.

Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.

P. Kovar, H. Kleinert, J. Polakowski, 1992, Hypertension.

Cyclopentanedi- and tricarboxylic acids as squalene synthase inhibitors: syntheses and evaluation.

D. Garvey, S. Rosenberg, W. Shen, 1998, Bioorganic & medicinal chemistry letters.

Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.

S. Ng, P. Kovar, S. Rosenberg, 2000, European journal of cancer.

Potent inhibitors of protein farnesyltransferase: heteroarenes as cysteine replacements.

S. Ng, P. Kovar, S. Rosenberg, 1999, Bioorganic & medicinal chemistry letters.

Overexpression of a Modified Human Malonyl-CoA Decarboxylase Blocks the Glucose-induced Increase in Malonyl-CoA Level but Has No Impact on Insulin Secretion in INS-1-derived (832/13) β-Cells*

H. Mulder, C. Newgard, Danhong Lu, 2001, The Journal of Biological Chemistry.

Effects of angiotensinase inhibitors on plasma protein binding and IC50 determinations of renin inhibitors.

S. Rosenberg, B. Dayton, W. Baker, 1992, Clinical chemistry.

New inhibitors of human renin that contain novel Leu-Val replacements.

J. Plattner, J. Cohen, J. Luly, 1987, Journal of medicinal chemistry.

New inhibitors of renin that contain novel phosphostatine Leu-Val replacements.

R. Maki, K. Marsh, J. Plattner, 1990, Journal of medicinal chemistry.

Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.

J A Mitchell, D. McComsey, B. Maryanoff, 1999, Journal of medicinal chemistry.

Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.

R. Maki, J. Plattner, H. Kleinert, 1987, Journal of medicinal chemistry.

Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.

S. Rosenberg, P. Marcotte, J. Plattner, 1987, Journal of medicinal chemistry.

New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.

J. Greer, G. Bolis, J. Plattner, 1988, Journal of medicinal chemistry.

Design of a well-absorbed renin inhibitor.

D. Egan, S. Rosenberg, H. Kleinert, 1991, Journal of medicinal chemistry.

Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.

D. Kempf, J. Plattner, J. Cohen, 1987, Journal of medicinal chemistry.

Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.

S. Ng, S. Rosenberg, H. Sham, 1999, Journal of medicinal chemistry.

1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors.

S. Rosenberg, R. Austin, W. Baker, 1992, Journal of medicinal chemistry.

C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.

D. Egan, W. Baker, J. Cohen, 1992, Journal of medicinal chemistry.

Renin inhibitors: C-terminal oxetanes as potent transition-state mimics.

S. Rosenberg, H. Kleinert, W. Baker, 1994, Bioorganic & medicinal chemistry.

Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.

D. Egan, S. Rosenberg, J. Polakowski, 1993, Journal of medicinal chemistry.

Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-7251

P. Kovar, S. Rosenberg, J. Polakowski, 1993, Journal of medicinal chemistry.

Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.

J. Wessale, K. Verburg, W. Baker, 1994, Journal of medicinal chemistry.

Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones.

Z. Zhang, P. Zhang, J. Wrobel, 2001, Bioorganic & medicinal chemistry letters.

Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.

S. Ng, D. Augeri, S. Rosenberg, 1998, Journal of medicinal chemistry.

Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.

S. Ng, P. Kovar, S. Rosenberg, 1999, Journal of medicinal chemistry.

In vitro and in vivo characterization of a novel nonsteroidal, species-specific progesterone receptor modulator, PRA-910.

R. Winneker, Z. Zhang, S. Lundeen, 2007, Ernst Schering Foundation symposium proceedings.

(1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor.

D. Garvey, S. Rosenberg, S. Fakhoury, 1997, Journal of medicinal chemistry.

Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.

R. Maki, D. Kempf, S. Rosenberg, 1990, Journal of medicinal chemistry.